you are here:

Unichem Laboratories Ltd.

BSE: 506690 | NSE: UNICHEMLAB |

Represents Equity.Intra - day transactions are permissible and normal trading is done in this category
Series: EQ | ISIN: INE351A01035 | SECTOR: Pharmaceuticals

BSE Live

Jul 30, 15:40
333.45 0.85 (0.26%)
Volume
AVERAGE VOLUME
5-Day
3,594
10-Day
6,179
30-Day
6,148
12,948
  • Prev. Close

    332.60

  • Open Price

    334.25

  • Bid Price (Qty.)

    0.00 (0)

  • Offer Price (Qty.)

    0.00 (0)

NSE Live

Jul 30, 15:57
333.20 0.40 (0.12%)
Volume
AVERAGE VOLUME
5-Day
51,261
10-Day
59,412
30-Day
50,602
46,239
  • Prev. Close

    332.80

  • Open Price

    334.90

  • Bid Price (Qty.)

    0.00 (0)

  • Offer Price (Qty.)

    333.20 (1)

Annual Report

For Year :
2019 2017 2016 2015 2014 2013 2011 2010 2009

Chairman's Speech

Dear Shareholders, Your company completes 50 years since it went public. I am happy to address you on this occasion. We take this opportunity to remember our founder Late Shri Amrut Mody who sowed the seeds for this tree to flourish. Your company recorded a turnover of over Rs. 1,000 Crores in this year, reflecting overall growth of 25.15%. With the changing circumstances particularly in the domestic market because of the Drug Price Control Order (DPCO) 2013 it is worth noting that the government has brought 348 medicines under the National List of Essential Medicines (NLEM) under price control which is based on market prices and not cost plus. It is heartening to see that finally the method of price fixation has been changed based on market forces. A few products of your company would attract the provision of the new price control and we would be taking effective steps to reduce the impact of the same. We have restructured our domestic business and while we would continue focusing on the growth of our chronic therapies we shall also endeavor to increase our share in the acute therapies so that our product basket becomes more balanced and complete. The initiatives taken last year on portfolio prioritization and sales force alignment are strategically yielding positive results and we hope to see this trend continue in the future. I would like to share with you that for a strong international formulation business it is important to have a back-up of our own APIs. This effort of backward integration in most of our formulations is ongoing and we are engaged in the exercise of expanding and augmenting our API facilities to meet the demand in the market. We have signed an agreement with Mylan Laboratories Limited for sale of our SEZ facility at Indore for a consideration of Rs. 160.50 Crores. The formalities are being processed and we would be able to complete the transaction shortly. The proceeds of the same will be utilized for the expansion of our existing facilities in Goa as well as exploring opportunities of acquiring API facilities for our needs. Our UK subsidiary Niche Generics Limited recorded a growth in revenues and has also reported a net profit. We are confident that finally we have turned the corner. Our US subsidiary is holding good promise and revenues in USA and North America market grew quite substantially. We are continuously adding to our list of filings so that we have a large basket to offer to our US customers. We have successfully shifted our Chemical and Formulation Development (PTD) Research Centres from Jogeshwari to the new research facility called Centre of Excellence [CoE] in Goa. All our R&D activities such as API chemical synthesis, Formulation Dosage Form development and Analytical Research are housed under one roof. This would enable us to co- ordinate our R&D activities more effectively. Our stake holders such as customers, business associates and shareholders have reposed their faith in us. I am grateful to them for their continued support and confidence in the management. I would also like to record my sincere appreciation for the commitment of our employees for their contribution. I remain confident that our well balanced strategy and determined implementation in the challenging macro environment will yield consistent high value for all our stake holders. Warm Regards Dr. Prakash A Mody Chairman & Managing Director